Turazza F M
Medicina (Firenze). 1990 Apr-Jun;10(2):193-4.
12,490 patients from the GISSI-2 trial were randomly allocated to alteplase (recombinant tissue-type plasminogen activator, t-PA) or streptokinase (SK) and beginning 12 hours after the start of thrombolytic therapy to subcutaneous heparin or no heparin. No significant differences in hospital mortality were found between the two thrombolytic treatments as well as between heparin and no heparin administration. The incidence of major cardiac complications was also very similar in the different groups. The incidence of major bleedings was significantly higher in SK and heparin treated patients, whereas the overall incidence of stroke was similar in all groups. SK and t-PA with or without post-thrombolytic heparin treatment appear equally effective and safe for use in routine conditions care, in all patients with acute myocardial infarction (AMI).
来自GISSI - 2试验的12490名患者被随机分配接受阿替普酶（重组组织型纤溶酶原激活剂，t - PA）或链激酶（SK）治疗，并在溶栓治疗开始12小时后给予皮下肝素或不给予肝素。两种溶栓治疗之间以及肝素给药组与未给药组之间的院内死亡率均无显著差异。不同组中心脏主要并发症的发生率也非常相似。SK联合肝素治疗的患者大出血发生率显著更高，而所有组中卒中的总体发生率相似。对于所有急性心肌梗死（AMI）患者，在常规护理中，无论是否进行溶栓后肝素治疗，SK和t - PA似乎同样有效且安全。
